April 9, 2021
2 min. read

Dermatology News Roundup: April 9th, 2021


This month, we’re sharing the most recent top stories in dermatology news. A new study published in the Journal of the American Academy of Dermatology determined that rashes associated with the Pfizer and Moderna vaccine are not dangerous. New trials with Abrocitinib show greater itch reduction compared to Dupilumab, and a new US study showed sunscreen use in Asian Americans were lower than in comparison to Non-Hispanic Whites.

partner banner

Read more on these stories below:

Study: Skin Reactions to COVID Vaccines Aren’t Dangerous WebMD, April 8, 2021

While it is true that the Pfizer-BioNTech and Moderna coronavirus vaccines can cause several kinds of skin reactions, these reactions go away quickly and aren’t dangerous, according to a study published in the Journal of the American Academy of Dermatology.

Itch Response Faster With Abrocitinib in Trial Comparing JAK Inhibitor to Dupilumab Medscape, March 25, 2021

An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis (AD), in a multicenter, randomized trial.

Asian-Americans Less Likely to Use Sunscreen Than Non-Hispanic Whites Medscape, March 29, 2021

Asian-American adults are significantly less likely to consistently use sunscreen than non-Hispanic whites, a new U.S. study suggests.

For Enthesitis in Psoriatic Arthritis, Target IL-23 Medpage Today, April 8, 2021

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.

Anxiety, depression reduce odds of achieving minimal disease activity in PsA Healio, March 23, 2021

Anxiety and depression symptoms reduce the likelihood of achieving sustained minimal disease activity in psoriatic arthritis, according to data published in Arthritis Care & Research.

Want to keep updated with Medly? Subscribe to our monthly newsletter!

UTM Source:UTM Campaign:UTM Content:UTM Medium:UTM Term:UTM Device:Landing Page:Company:Last Name:
Join Medly